Muken Ross 4
4 · SOPHiA GENETICS SA · Filed Jun 23, 2026
Research Summary
AI-generated summary of this filing
SOPHiA GENETICS (SOPH) President Muken Ross Sells 422 Shares
What Happened Muken Ross, President of SOPHiA GENETICS SA (SOPH), sold 422 shares on June 22, 2026, in an open‑market transaction. The reported weighted average sale price was $5.38 per share, for proceeds of approximately $2,270. This sale was to satisfy tax withholding obligations related to RSUs that vested on June 18, 2026.
Key Details
- Transaction date: 2026-06-22 (filed 2026-06-23)
- Action: Sale (S) of 422 shares; weighted average price $5.38; total ≈ $2,270
- Price range: shares sold in multiple trades at $5.33–$5.48 (Reporting Person can provide per‑trade breakdown on request) (F2)
- Reason/footnote: Shares sold in open market to satisfy tax withholding on RSU vesting; sales executed under a pre‑established Rule 10b5‑1(c) plan (non‑discretionary) (F1)
- Shares owned after transaction: Not reported in the provided Form 4 data
- Timeliness: Filed the next day (no late filing flag)
Context This was a routine, tax‑related sale under a 10b5‑1 plan rather than a discretionary divestiture. Such transactions commonly occur when restricted stock units vest and do not necessarily signal a change in the insider’s view of the company.
Insider Transaction Report
Form 4
Muken Ross
DirectorChief Executive Officer
Transactions
- Sale
Ordinary Shares
[F1][F2]2026-06-22$5.38/sh−422$2,270→ 680,489 total
Footnotes (2)
- [F1]Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on June 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.33 to $5.48, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken|2026-06-23